TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Immutep Ltd ( (AU:IMM) ) has issued an update.
Immutep Ltd announced a change in the director’s interest, where Mr. Pete Meyers converted 388,889 performance rights into fully paid ordinary shares. This change reflects the director’s compensation strategy, where he receives part of his fees in performance rights, aligning his interests with those of the shareholders.
The most recent analyst rating on (AU:IMM) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Immutep Ltd stock, see the AU:IMM Stock Forecast page.
More about Immutep Ltd
Immutep Ltd is a biotechnology company that focuses on developing immunotherapy treatments for cancer and autoimmune diseases. The company is listed on the Australian Securities Exchange under the ticker symbol IMM.
Average Trading Volume: 2,480,709
Technical Sentiment Signal: Hold
Current Market Cap: A$426.9M
For an in-depth examination of IMM stock, go to TipRanks’ Overview page.